Cargando…

1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis

BACKGROUND: The mortality in liver cirrhosis was reported to be greater than that in the five major cancers. Infection further increases the mortality of patients with cirrhosis by four fold. Considering the greatly increased mortality from infection in patients with cirrhosis, early diagnosis and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae-Hwan, Kim, Jihye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809150/
http://dx.doi.org/10.1093/ofid/ofz360.1289
_version_ 1783461914288848896
author Kim, Tae-Hwan
Kim, Jihye
author_facet Kim, Tae-Hwan
Kim, Jihye
author_sort Kim, Tae-Hwan
collection PubMed
description BACKGROUND: The mortality in liver cirrhosis was reported to be greater than that in the five major cancers. Infection further increases the mortality of patients with cirrhosis by four fold. Considering the greatly increased mortality from infection in patients with cirrhosis, early diagnosis and prompt treatments should be compulsory to save patients’ lives. However, adherence to such basic principle for patients with cirrhosis is not easy for clinicians engaged in the treatment of pyogenic vertebral osteomyelitis (PVO). Therefore, the mortality rate is expected to be high. However, no reports have described the mortality rate in this patient group. METHODS: A retrospective study was conducted to investigate the treatment outcome in PVO patients with cirrhosis, and to identify the predictors of their mortality. Mortality was divided into two categories, 30-day and 90-day mortality. A stepwise multivariate logistic regression model was used to identify predictors of mortality. Due to high mortality rate, the clinical outcome was investigated in patients with at least 90-day survival. RESULTS: Eighty-five patients were identified after initial exclusion. The patients’ mean age was 60.5 years, and 50 patients were male. The early mortality rates within 30 and 90 days were 17.6% and 36.5%, respectively (Table 1). Multivariate analysis revealed that increased age, CTP class C, and bacteremia at the time of PVO diagnosis were predictors of 30-day mortality while higher MELD score, presence of combined infection, and multiple spinal lesions were predictors of 90-day mortality (Figure 1, Table 2). The duration of antibiotic treatment and the length of hospital stay (from the PVO diagnosis) were longer in CTP C patients; however, they were statistically insignificant (Table 3). Recurrence of PVO was more common in CTP C patients (P = 0.028) (Table 3). CONCLUSION: Attention should be paid to the high mortality between 30 and 90 days after PVO diagnosis (18.8%), which was higher than the 30-day mortality. Liver function was consistently strong predictor of mortality in PVO patients with cirrhosis. The high-risk patients should be targeted for an aggressive diagnostic approach using spinal MRI and intensive medicosurgical treatment. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809150
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68091502019-10-28 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis Kim, Tae-Hwan Kim, Jihye Open Forum Infect Dis Abstracts BACKGROUND: The mortality in liver cirrhosis was reported to be greater than that in the five major cancers. Infection further increases the mortality of patients with cirrhosis by four fold. Considering the greatly increased mortality from infection in patients with cirrhosis, early diagnosis and prompt treatments should be compulsory to save patients’ lives. However, adherence to such basic principle for patients with cirrhosis is not easy for clinicians engaged in the treatment of pyogenic vertebral osteomyelitis (PVO). Therefore, the mortality rate is expected to be high. However, no reports have described the mortality rate in this patient group. METHODS: A retrospective study was conducted to investigate the treatment outcome in PVO patients with cirrhosis, and to identify the predictors of their mortality. Mortality was divided into two categories, 30-day and 90-day mortality. A stepwise multivariate logistic regression model was used to identify predictors of mortality. Due to high mortality rate, the clinical outcome was investigated in patients with at least 90-day survival. RESULTS: Eighty-five patients were identified after initial exclusion. The patients’ mean age was 60.5 years, and 50 patients were male. The early mortality rates within 30 and 90 days were 17.6% and 36.5%, respectively (Table 1). Multivariate analysis revealed that increased age, CTP class C, and bacteremia at the time of PVO diagnosis were predictors of 30-day mortality while higher MELD score, presence of combined infection, and multiple spinal lesions were predictors of 90-day mortality (Figure 1, Table 2). The duration of antibiotic treatment and the length of hospital stay (from the PVO diagnosis) were longer in CTP C patients; however, they were statistically insignificant (Table 3). Recurrence of PVO was more common in CTP C patients (P = 0.028) (Table 3). CONCLUSION: Attention should be paid to the high mortality between 30 and 90 days after PVO diagnosis (18.8%), which was higher than the 30-day mortality. Liver function was consistently strong predictor of mortality in PVO patients with cirrhosis. The high-risk patients should be targeted for an aggressive diagnostic approach using spinal MRI and intensive medicosurgical treatment. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809150/ http://dx.doi.org/10.1093/ofid/ofz360.1289 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kim, Tae-Hwan
Kim, Jihye
1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title_full 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title_fullStr 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title_full_unstemmed 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title_short 1425. Treatment Outcomes in Patients with Pyogenic Vertebral Osteomyelitis Who Have Cirrhosis
title_sort 1425. treatment outcomes in patients with pyogenic vertebral osteomyelitis who have cirrhosis
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809150/
http://dx.doi.org/10.1093/ofid/ofz360.1289
work_keys_str_mv AT kimtaehwan 1425treatmentoutcomesinpatientswithpyogenicvertebralosteomyelitiswhohavecirrhosis
AT kimjihye 1425treatmentoutcomesinpatientswithpyogenicvertebralosteomyelitiswhohavecirrhosis